Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference
(Thomson Reuters ONE) -
Lund, Sweden, September 5, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the Rodman & Renshaw Annual Global Investment Conference
held September 8-10, 2013 in New York, USA. During the presentation, an update
regarding Active Biotech's development programs will be provided.
The presentation will include the laquinimod project, a novel oral
immunomodulatory drug primarily for the treatment of multiple sclerosis,
licensed to Teva Pharmaceutical, the Phase III prostate cancer project
tasquinimod in co-development with Ipsen, as well as ANYARA, Active Biotech's
novel concept for tumor therapy of primarily renal cell cancer. Also, the
project 57-57 (paquinimod) and the pre-clinical ISI project will be
presented.
The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to - www.activebiotech.com.
The presentation will take place on September 9, at 3:40 p.m. EDT (Eastern
Daylight Time) / 21:40 Central European Summer Time.
For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam(at)activebiotech.com
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In addition, laquinimod is in clinical development for Crohn's and Lupus. The
company also has one additional project in clinical development, the orally
administered compound paquinimod (57-57) for systemic sclerosis. Please visit
www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 8:30 a.m. CET on September 5, 2013.
Active Biotech to Present at the Rodman & Renshaw Annual Global Inves:
http://hugin.info/1002/R/1726877/576340.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1726877]
Unternehmensinformation / Kurzprofil:
Datum: 05.09.2013 - 08:30 Uhr
Sprache: Deutsch
News-ID 293744
Anzahl Zeichen: 3195
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 150 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
